Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy

Autologous T cells engineered to express a CD19-specific chimeric antigen receptor (CAR) have produced impressive minimal residual disease-negative (MRD-negative) complete remission (CR) rates in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, the factors asso...

Full description

Saved in:

Bibliographic Details
Published in:	Blood Vol. 133; no. 15; p. 1652
Main Authors:	Hay, Kevin A, Gauthier, Jordan, Hirayama, Alexandre V, Voutsinas, Jenna M, Wu, Qian, Li, Daniel, Gooley, Ted A, Cherian, Sindhu, Chen, Xueyan, Pender, Barbara S, Hawkins, Reed M, Vakil, Aesha, Steinmetz, Rachel N, Schoch, Gary, Chapuis, Aude G, Till, Brian G, Kiem, Hans-Peter, Ramos, Jorge D, Shadman, Mazyar, Cassaday, Ryan D, Acharya, Utkarsh H, Riddell, Stanley R, Maloney, David G, Turtle, Cameron J
Format:	Journal Article
Language:	English
Published:	United States 11.04.2019
Subjects:	Adult Antigens, CD19 - immunology Disease-Free Survival Female Hematopoietic Stem Cell Transplantation Humans Immunotherapy, Adoptive - methods Lymphocyte Depletion Male Middle Aged Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - therapy Receptors, Chimeric Antigen Remission Induction - methods Salvage Therapy - methods Young Adult
ISSN:	1528-0020, 1528-0020
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!